The DOI matches its Crossref record; 428 of the 428 references it cites were found in a registry or an index.
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Open accessAbstract
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in a variety of in vivo models.Hypoxia has been shown to be a major inducer of VEGF gene transcription.The tyrosine kinases Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR-2) are highaffinity VEGF receptors.The role of VEGF in developmental angiogenesis is emphasized by the finding that loss of a single VEGF allele results in defective vascularization and early embryonic lethality.VEGF is critical also for reproductive and bone angiogenesis.Substantial evidence also implicates VEGF as a mediator of pathological angiogenesis.In situ hybridization studies demonstrate expression of VEGF mRNA in the majority of human tumors.Anti-VEGF monoclonal antibodies and other VEGF inhibitors block the growth of several tumor cell lines in nude mice.Clinical trials with various VEGF inhibitors in a variety of malignancies are ongoing.Very recently, an anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the Food and Drug Administration as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy.Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.(Endocrine Reviews 25: 581-611, 2004) I. Introduction II.Historical Note on Angiogenic Factors III.Identification of VEGF IV.Activities of VEGF A. Mitogenesis, angiogenesis, and endothelial survival B. Effects of VEGF on bone marrow cells and hematopoiesis C. Enhancement of vascular permeability and hemodynamic effects V. VEGF Isoforms VI.Regulation of VEGF Gene Expression A. Oxygen tension B. Growth factors, hormones, and oncogenes VII.VEGFRs A. VEGFR-1 (Flt-1) B. VEGFR-2 (KDR, human; Flk-1, mouse) C. Neuropilin (NP)1 and NP2 VIII.Role of VEGF in Physiological Angiogenesis A. Embryonic and postnatal development B. Skeletal growth and endochondral bone formation C. Angiogenesis in endocrine glands IX.Role of VEGF in Pathological Conditions A. Solid tumors B. Hematological malignancies C. Intraocular neovascular syndromes D. Inflammatory disorders and brain edema
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Self-citationLi, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Cited by
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wound repair and regeneration: Mechanisms, signaling, and translation
Eming, S. A., Martin, P., & Tomic-Canic, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009337 · Cited by 3,562
“With the discovery of VEGF more than 30 years ago and with its envisioned potential for vascular therapy, it was presumed to be the solution for therapeutic angiogenesis (67).”
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Self-citationDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“There is now much evidence to indicate that VEGF 165 is the most physiologically relevant isofor”
BackgroundSelf-citationTumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis
Hellström, M., Phng, L.-K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., Nilsson, A.-K., Karlsson, L., Gaiano, N., et al. (2007) · Nature · doi:10.1038/nature05571 · Cited by 1,775
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Self-citationBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Self-citationElectrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
Langley, R. R., & Fidler, I. J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26031 · Cited by 958
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
Physiological and pathological cardiac hypertrophy
Shimizu, I., & Minamino, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.001 · Cited by 887
Claesson‐Welsh, L., & Welsh, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12019 · Cited by 868
Roland, L., Grau, M., Matena, J., Teske, M., Gieseke, M., Kampmann, A., Beyerbach, M., Murua Escobar, H., Haferkamp, H., Gellrich, N.-C., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010001 · Cited by 862
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Self-citationTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
“VEGF-A is a well-characterized regulator of angiogenesis and several anti-VEGF strategies have been implemente”
BackgroundSelf-citationThe biology of vascular endothelial growth factors
TAMMELA, T., ENHOLM, B., ALITALO, K., & PAAVONEN, K. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.002 · Cited by 838
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 799
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Lohela, M., Bry, M., Tammela, T., & Alitalo, K. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.012 · Cited by 738
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001115 · Cited by 725
“Targeted gene disruption experiments in mice have revealed that loss of even a single allele of VEGF (hemizygosity) induces an embryonic lethal phenotype with gross vascular abnormalities demonstrating a dosedependent requirement for VEGF in vasculogenesis (Ferrara, 2004).”
BackgroundDevelopmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Self-citationRomero, R., Nien, J. K., Espinoza, J., Todem, D., Fu, W., Chung, H., Kusanovic, J. P., Gotsch, F., Erez, O., Mazaki-Tovi, S., et al. (2008) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050701830480 · Cited by 675
MICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.007 · Cited by 664
Zhu, X., Wu, S., Dahut, W. L., & Parikh, C. R. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.11.039 · Cited by 632
Medicinal Chemistry of Combretastatin A4: Present and Future Directions
Tron, G. C., Pirali, T., Sorba, G., Pagliai, F., Busacca, S., & Genazzani, A. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512903 · Cited by 629
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Self-citationCrawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Self-citationNeri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective
Kowanetz, M., & Ferrara, N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1520 · Cited by 564
Self-citationBiology of vascular endothelial growth factors
Roy, H., Bhardwaj, S., & Ylä-Herttuala, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.087 · Cited by 537
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
Peach, C. J., Mignone, V. W., Arruda, M. A., Alcobia, D. C., Hill, S. J., Kilpatrick, L. E., & Woolard, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041264 · Cited by 512
Advances in targeted therapy for esophageal cancer
Yang, Y.-M., Hong, P., Xu, W. W., He, Q.-Y., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 508
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503
Anti-cancer chalcones: Structural and molecular target perspectives
Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.004 · Cited by 495
Multimodality Molecular Imaging of Tumor Angiogenesis
Cai, W., & Chen, X. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045922 · Cited by 494
Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives
Simó, R., & Hernández, C. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.005 · Cited by 490
Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.192 · Cited by 486
RICH, R. M., ROSENFELD, P. J., PULIAFITO, C. A., DUBOVY, S. R., DAVIS, J. L., FLYNN, H. W., GONZALEZ, S., FEUER, W. J., LIN, R. C., LALWANI, G. A., et al. (2006) · Retina · doi:10.1097/01.iae.0000225766.75009.3a · Cited by 484
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
Self-citationVascular Endothelial Growth Factors
Ylä-Herttuala, S., Rissanen, T. T., Vajanto, I., & Hartikainen, J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.053 · Cited by 480
Co3O4 Nanoparticles with Multi-Enzyme Activities and Their Application in Immunohistochemical Assay
Dong, J., Song, L., Yin, J.-J., He, W., Wu, Y., Gu, N., & Zhang, Y. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am405009f · Cited by 454
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Niu, G., & Chen, X. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 451
Qin, Y., & Hurley, L. H. (2008) · Biochimie · doi:10.1016/j.biochi.2008.02.020 · Cited by 450
Role and Therapeutic Potential of VEGF in the Nervous System
Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., & Carmeliet, P. (2009) · Physiological Reviews · doi:10.1152/physrev.00031.2008 · Cited by 448
Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
Ramakrishnan, S., Anand, V., & Roy, S. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9531-7 · Cited by 442
Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis
Shibuya, M. (2006) · Angiogenesis · doi:10.1007/s10456-006-9055-8 · Cited by 437
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Saltz, L. B., Lenz, H.-J., Kindler, H. L., Hochster, H. S., Wadler, S., Hoff, P. M., Kemeny, N. E., Hollywood, E. M., Gonen, M., Quinones, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0949 · Cited by 425
Expression of angiogenic growth factors by uterine natural killer cells during early pregnancy
Lash, G. E., Schiessl, B., Kirkley, M., Innes, B. A., Cooper, A., Searle, R. F., Robson, S. C., & Bulmer, J. N. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0406250 · Cited by 423
Sheffer, M., Bacolod, M. D., Zuk, O., Giardina, S. F., Pincas, H., Barany, F., Paty, P. B., Gerald, W. L., Notterman, D. A., & Domany, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902232106 · Cited by 414
Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration
Kent Leach, J., Kaigler, D., Wang, Z., Krebsbach, P. H., & Mooney, D. J. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.01.033 · Cited by 411
Angiogenesis: Where Do We Stand Now?
Simons, M. (2005) · Circulation · doi:10.1161/01.cir.0000159345.00591.8f · Cited by 411
Decidualization of the human endometrium
Okada, H., Tsuzuki, T., & Murata, H. (2018) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12088 · Cited by 407
The role of VEGF receptors in angiogenesis; complex partnerships
Cébe-Suarez, S., Zehnder-Fjällman, A., & Ballmer-Hofer, K. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5426-3 · Cited by 405
Vascular endothelial growth factor in the lung
Voelkel, N. F., Vandivier, R. W., & Tuder, R. M. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00185.2005 · Cited by 403
Angiogenesis in the atherosclerotic plaque
Camaré, C., Pucelle, M., Nègre-Salvayre, A., & Salvayre, R. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.007 · Cited by 401
Cellular and Molecular Mechanisms of Gastrointestinal Ulcer Healing
Tarnawski, A. S. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2803-6 · Cited by 396
Zagzag, D., Lukyanov, Y., Lan, L., Ali, M. A., Esencay, M., Mendez, O., Yee, H., Voura, E. B., & Newcomb, E. W. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700482 · Cited by 396
Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer
Khorana, A. A., Ahrendt, S. A., Ryan, C. K., Francis, C. W., Hruban, R. H., Hu, Y. C., Hostetter, G., Harvey, J., & Taubman, M. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2351 · Cited by 394
The Role of MSC in Wound Healing, Scarring and Regeneration
Guillamat-Prats, R. (2021) · Cells · doi:10.3390/cells10071729 · Cited by 393
Regulation of angiogenesis: Wound healing as a model
EMING, S., BRACHVOGEL, B., ODORISIO, T., & KOCH, M. (2007) · Progress in Histochemistry and Cytochemistry · doi:10.1016/j.proghi.2007.06.001 · Cited by 392
(2011) · InTech eBooks · doi:10.5772/749 · Cited by 386
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya-Feldstein, J., Cordon-Cardo, C., Celeste Simon, M., Rafii, S., & Pandolfi, P. P. (2006) · Nature · doi:10.1038/nature05029 · Cited by 378
Vascular endothelial growth factor family of ligands and receptors: Review
Otrock, Z. K., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2006.12.003 · Cited by 376
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
Aptamers in the Therapeutics and Diagnostics Pipelines
Kaur, H., Bruno, J. G., Kumar, A., & Sharma, T. K. (2018) · Theranostics · doi:10.7150/thno.25958 · Cited by 366
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
Transcriptional Control of Endothelial Cell Development
De Val, S., & Black, B. L. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.014 · Cited by 346
“Current therapies for inhibiting angiogenic vessel growth in these and other disorders are primarily aimed at blocking VEGF and other signaling pathways (Ferrara, 2004; Goh et al., 2007).”
BackgroundAngiogenesis in Gliomas: Biology and Molecular Pathophysiology
Fischer, I., Gagner, J., Law, M., Newcomb, E. W., & Zagzag, D. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00115.x · Cited by 350
Uterine natural killer cells initiate spiral artery remodeling in human pregnancy
Robson, A., Harris, L. K., Innes, B. A., Lash, G. E., Aljunaidy, M. M., Aplin, J. D., Baker, P. N., Robson, S. C., & Bulmer, J. N. (2012) · The FASEB Journal · doi:10.1096/fj.12-210310 · Cited by 349
Expression of P2X7 Receptor Increases In Vivo Tumor Growth
Adinolfi, E., Raffaghello, L., Giuliani, A. L., Cavazzini, L., Capece, M., Chiozzi, P., Bianchi, G., Kroemer, G., Pistoia, V., & Di Virgilio, F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1947 · Cited by 347
Biocompatible Materials for Continuous Glucose Monitoring Devices
Nichols, S. P., Koh, A., Storm, W. L., Shin, J. H., & Schoenfisch, M. H. (2013) · Chemical Reviews · doi:10.1021/cr300387j · Cited by 347
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Self-citationPhage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT
AVERY, R. L. (2006) · Retina · doi:10.1097/00006982-200603000-00016 · Cited by 342
Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G., & Mignatti, P. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21706 · Cited by 340
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Le, X., Nilsson, M., Goldman, J., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt-Moller, B., Wolff, K., Visseren-Grul, C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 339
Vascular Biology and the Skeleton
Brandi, M. L., & Collin-Osdoby, P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050917 · Cited by 338
Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema
Arevalo, J. F., Fromow-Guerra, J., Quiroz-Mercado, H., Sanchez, J. G., Wu, L., Maia, M., Berrocal, M. H., Solis-Vivanco, A., & Farah, M. E. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.12.028 · Cited by 335
Sex Differences in Cancer: Epidemiology, Genetics and Therapy
Kim, H.-I., Lim, H., & Moon, A. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.103 · Cited by 315
Bremnes, R. M., Camps, C., & Sirera, R. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.09.005 · Cited by 330
VEGF-A: a critical regulator of blood vessel growth
Ferrara, N. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0170 · Cited by 327
Self-citationImmunological mechanisms in the pathogenesis of diabetic retinopathy
Adamis, A. P., & Berman, A. J. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0111-x · Cited by 322
Jo, N., Mailhos, C., Ju, M., Cheung, E., Bradley, J., Nishijima, K., Robinson, G. S., Adamis, A. P., & Shima, D. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050588 · Cited by 322
Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314
New developments in the diagnosis and treatment of thyroid cancer
Schneider, D. F., & Chen, H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21195 · Cited by 316
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Self-citationThe Role of Growth Factors and Cytokines during Implantation: Endocrine and Paracrine Interactions
Guzeloglu-Kayisli, O., Kayisli, U., & Taylor, H. (2009) · Seminars in Reproductive Medicine · doi:10.1055/s-0028-1108011 · Cited by 314
In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., Brouwers, A. H., van Dongen, G. A., Perk, L. R., & Lub-de Hooge, M. N. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.041301 · Cited by 313
Metadata
- Authors
- Ferrara, N.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2004-08-01
- Volume
- 25
- Issue
- 4
- Pages
- 581-611
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2077129920
- Cited by
- 3,687
- References
- 428
- FWCI
- 54.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.